Metabolic and hormonal effects of melatonin and/or magnesium supplementation in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial
Alizadeh M, Karandish M, Asghari Jafarabadi M, Heidari L, Nikbakht R, Babaahmadi Rezaei H, Mousavi R
Nutrition & metabolism · 37 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (clasificado por nuestro filtro de IA)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Universidad u hospital
- Ahvaz Jundishapur University of Medical Sciences
- Universidad u hospital
- University of Tabriz
- Universidad u hospital
- Tabriz University of Medical science
- Subvenciones
- Ahvaz Jundishapur University of Medical Sciences (NRC-9815)
Según 3 financiadores declarados y la declaración de financiación del texto completo.
Publicación
- Publicado
- 2021-06-06 · Nutr Metab (Lond) · vol. 18 · número 1 · pág. 57
- Editorial
- BioMed Central
- Citado
- 52 citas · más que el 93% de estudios similares · 3.3× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 63 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Magnesium in Health and Disease · Ovarian function and disorders · Menopause: Health Impacts and Treatments
- Palabras clave
- Melatonin, Polycystic ovary, Endocrinology, Internal medicine, Medicine, Placebo, Insulin resistance, Testosterone (patch), Lipid profile, Insulin, Cholesterol
7 autores
- Mohammad Alizadeh🇮🇷University of Tabriz
- Majid Karandish🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Mohammad Asghari Jafarabadi🇮🇷Zanjan University of Medical Sciences; University of Tabriz
- Lida Heidari🇮🇷Isfahan Fertility and Infertility Center
- Roshan Nikbakht🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Hossein Babaahmadi‐Rezaei🇮🇷Ahvaz Jundishapur University of Medical Sciences
- Reihaneh Mousavi🇮🇷 · autor de correspondenciaAhvaz Jundishapur University of Medical Sciences
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders among women of reproductive age. This study was designed to investigate the effects of melatonin and/or magnesium supplementation on metabolic profile and levels of sex hormones in PCOS women.
Methods
In an 8-week randomized double-blind placebo-controlled trial, 84 subjects with PCOS aged 18-40 years were randomly assigned based on the random block procedure to take magnesium, melatonin, magnesium plus melatonin, and placebo. Fasting blood samples were obtained at the beginning and end of the study.
Results
After intervention, the mean Pittsburg Sleep Quality Index score decreased significantly in both co-supplementation and melatonin groups (P < 0.001). Magnesium supplementation in combination with melatonin resulted in a significant greater decrease in testosterone concentrations compared with the placebo (P < 0.05). Co-supplementation of magnesium-melatonin had significantly reduced serum insulin levels (geometric means difference: - 1.11 (mIU/mL) (percent change: - 15.99)), homeostasis model of assessment-insulin resistance (HOMA-IR) (- 0.28 (- 18.66)), serum cholesterol (mean difference: - 16.08 (mg/dl) [95% CI - 24.24, - 7.92]), low-density lipoprotein cholesterol (LDL-C) - 18.96 (mg/dl) [- 28.73, - 9.20]) and testosterone levels (- 0.09 (ng/ml) (- 25.00)), as compared to the baseline values (P < 0.05). An increase in serum high-density lipoprotein cholesterol (HDL-C) levels was also observed following the administration of the melatonin alone (2.76 (mg/dl) [0.57, 4.95]) or in combination with magnesium (2.19 (mg/dl) [0.61, 3.77]) (P < 0.05).
Conclusions
Co-supplementation with magnesium and melatonin had beneficial effects on sleep quality and total testosterone. Additionally, melatonin supplementation alone was found to be associated with a significant reduction in PSQI score. Moreover, combined melatonin and magnesium supplementation was more effective in improving serum levels of cholesterol, LDL-C, HDL-C and insulin, and HOMA-IR.
Trial registration
Iranian Registry of Clinical Trial. http://www.irct.ir : IRCT20191130045556N1, January 2020.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.